Alnylam Pharmaceuticals Inc. (ALNY) PT Set at $106.00 by Piper Jaffray Cos.
Piper Jaffray Cos. set a $106.00 price objective on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) in a research report report published on Thursday morning. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.
ALNY has been the topic of a number of other reports. Janney Montgomery Scott started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, September 28th. They set a neutral rating and a $74.00 price objective on the stock. Credit Suisse Group AG set a $145.00 price target on Alnylam Pharmaceuticals and gave the stock a buy rating in a report on Friday, September 30th. FBR & Co reiterated a buy rating on shares of Alnylam Pharmaceuticals in a report on Thursday, September 8th. Morgan Stanley downgraded Alnylam Pharmaceuticals from an overweight rating to an equal weight rating and reduced their price target for the stock from $38.00 to $36.00 in a report on Friday, October 7th. Finally, Leerink Swann reiterated a buy rating on shares of Alnylam Pharmaceuticals in a report on Monday, September 26th. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $79.50.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.83 on Thursday. The firm has a 50-day moving average price of $68.44 and a 200 day moving average price of $65.73. Alnylam Pharmaceuticals has a 12-month low of $33.16 and a 12-month high of $110.75. The company’s market capitalization is $2.99 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The business had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.09 million. During the same period in the prior year, the business posted ($0.85) earnings per share. The company’s quarterly revenue was up .2% compared to the same quarter last year. On average, equities research analysts predict that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current year.
In other news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.00% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth $128,000. Seven Eight Capital LLC boosted its stake in Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 1,800 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth $175,000. Bank of Montreal Can acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth $193,000. Finally, BlueMountain Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 1,500 shares during the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.